Kornimate/medical-research-clean huggingface dataset:
detection of pre-diabetes in overweight and obese children

Conditions: Pre-Diabetes

Summary: descriptive cross section study to detect prediabetes in overweight and obese children and adolescents in assiut governorate and to find out the possible risk factors.

childhood obesity has reached epidemic levels in developed as well as in developing countries, overweight and obesity in childhood have significant impact on both physical and psychological health. childhood obesity has been linked to numerous medical conditions. these conditions include : fatty liver disease, sleep apnea, type 2 diabetes, asthma, cardiovascular disease, high cholesterol, cholelithiasis (gallstones), glucose intolerance and insulin resistance, etc. obesity is associated with prediabetes , a significant risk factor for development of type 2 diabetes mellitus t2dm and its accompanying complications. in some populations, type 2 diabetes is now the dominant form of diabetes in children and adolescents. prediabetes is defined by a fasting glucose level of 100 to 125 mg/dl , glycated hemoglobin level (hba1c) of 5.7% to 6.4% , or a glucose level of 140 to 199 mg/dl measured 2 hours after a 75-g oral glucose load. approximately 10% of people with prediabetes progress to having diabetes each year. the vast majority of pediatric cases occur after age 10, with the peak age for presentation occurring at mid-puberty (approximately age 14 years). the ada recommends screening for type 2 diabetes in children after onset of puberty or age 10 years who are overweight (bmi ≥85th percentile) or obese (bmi ≥95th percentile) and have one or more additional risk factors for diabetes. one report in jama pediatrics found that nearly one in three adolescents and teens has prediabetes and the rate among 12 to 19 year-olds more than doubled between 1999-2002 and 2015-2018, jumping from 12 percent to 28 percent. however , no enough data are available regarding prevalence and risk factors of prediabetes in overweight and obese youth particularly in our locality.

Eligibility criteria:
inclusion criteria: * both sexes , aged (10-18) years. * body mass index calculated as weight in kg/(height in meters)2 : * over weight \> 85% percentile * obese \> 95% percentile " on egyptian growth chart " exclusion criteria: * • children and adolescents with type 2 diabetes mellitus. * children and adolescents with drug history affecting blood glucose level as corticosteroids. * children and adolescents with any condition affecting blood glucose level as cushing disease.
a phase i trial of hdfl48 in recurrent or metastatic colorectal cancers

Conditions: Recurrent or Metastatic Colorectal Cancer

Summary: to determine the maximum tolerated dose and dose limiting toxicity of 5-fu and leucovorin with novel 48-hour infusion schedule, and to collect toxicity profile at different dose level of 5-fu/lv 48-hour infusion.

colorectal cancer is one of the major in taiwan.it caused 3128 deaths in 1999, and represented the no.3 cancer killer in both male and female population of taiwan. recently, evidence has accumulated that weekly, 24-hour infusion of high-dose 5-fu may improve the response rate and survival time compared with 5-fu bolus regiment. in a randomized multicenter trial of metastatic colorectal cancer, kohne et al reported an overall response rate of 44%and a median survival time of 16 months using a weekly-times-six schedule of infusional 5-fu (2600mg/m2 24-hours infusion). in another randomized study for advanced colorectal cancer, de gramont et al reported a significantly better outcome in patients treated by a similar schedule which combined "bolus plus infusional" 5-fu compared to "bolus" 5-fu. these results suggest that 24-or 48-hour infusion of high-dose 5-fu is more effective than the conventional bolus schedules.

Eligibility criteria:
inclusion criteria: * pathologically confirmed recurrent or metastatic colorectal adenocarcinoma * patients are indicated for 5-fu (1st-line after recurrence/metastasis), or have failed 5-fu ,treatment with other schedules * at least one bi-dimensionally measurable lesion(s) * previous c/t, r/t \>= 4 weeks * kps \> 50% * age \>= 18 years * fasting tg \> 70 mg/dl (within 7 days) * wbc \>= 3,000/ul or anc \>= 1,500/ul * plt \>= 75,000/ul * cre\<= 1.5 mg/dl * proteinuria \< 1+ * normal t-bil * ast/ alt \<= 3.5-fold of uln exclusion criteria: * concomitant anticancer therapy or radiotherapy * cns metastasis * pregnant women * patients who have second malignancy * symptomatic heart disease (significant arrhythmia, chf or mi within 3 months of entry) * active infection exists * extensive liver disease or liver cirrhosis * patients who refuse port-a catheter implantation

Keywords: colorectal cancer, maximum tolerated dose
the cohort for patient-reported outcomes, imaging and trial inclusion in metastatic brain disease (coimbra)

Conditions: Brain Metastases, Adult; Brain Neoplasms, Adult, Malignant

Summary: the incidence of brain metastases is expected to increase because of better treatments of primary tumours. novel diagnostic and therapeutic techniques are continuously being developed, all of which need thorough evaluation before they can be implemented in clinical routine. randomized controlled trials are the gold standard to do so, but they have shown many challenges, especially when applied in a cancer setting. .the 'cohort multiple randomized controlled trial (cmrct)' design is a promising design for multiple (simultaneous) randomized evaluations of experimental interventions, with potential for increased recruitment, comparability and long-term outcomes as a standard. this design will speed up the process of translating treatment innovations to the daily clinic.

the coimbra cohort is a prospective cohort, which will serve as a facility for efficient, systematic and simultaneous evaluation of new interventions and mri sequences and prospective outcome studies (including prediction modelling). coimbra patients will be followed prospectively and information on survival, symptoms, qol (patient and caregiver), cognition, toxicity and daily functioning in relation to treatment will be collected prospectively. patients will receive the regular optimal clinical care according to the current guidelines when not participating in cmrct's.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years; * either radiographic and/or histologic proof of metastatic brain disease, or eligible for prophylactic cranial irradiation; * referred to the department of radiotherapy for cranial irradiation. exclusion criteria: * mental disorder or cognitive dysfunction that hinder the patient's ability to understand the informed consent procedure and/or study details; * patients with severe psychiatric disorders; * inability to understand the dutch language.

Keywords: radiotherapy (rt) qol,quality of life neurocognition brain metastases cranial irradiation neoplasm metastasis prognosis survival prospective
hfs in the assessement and management of severe asthma attack among fifth year medical school students

Conditions: Asthma

Summary: bedside clinical case learning, such for respiratory distress, represent a challenge for medical teachers, especially in critical conditions. in fact, this kind of learning implicate the presence of an appropriate case (the patient itself), framework and may be time consuming which could compromise the patient's safety and wellbeing. new pedagogic tools have emerged to strengthen the medical reasoning and the acquisition of knowledge. in recent years, the development of medical simulation has found a growing interest in the medical teaching field. contextualization, reproducibility and reliability are the characteristics of high-fidelity simulation (hfs) which guarantee a lifetime experience of clinical conditions without putting at risk patient's safety and comfort. the aim of this study is to assess the impact of hfs on fifth year medical students learning skills in the assessement and management of an acute asthma attack in the emergency room, and to compares it to other modern teaching tools such as "video-case"


Eligibility criteria:
inclusion criteria: * all fifth year medical students allocated to the one month internship period in the emergency departement. exclusion criteria: * students refusing to participate in the protocol.
broad-spectrum cognitive remediation: effects of a brain plasticity-based program in mild traumatic brain injury

Conditions: Traumatic Brain Injury

Summary: the primary objective of this study is to evaluate the effects of plasticity-based, adaptive cognitive remediation on the cognitive abilities, functional status and quality of life of soldiers and veterans diagnosed with persistent post-concussive symptoms (ppcs) following a mild traumatic brain injury (mtbi, also referred to as a concussion, or blast exposure), as compared to a computer-based control.

this study is a multi-site, prospective, parallel arm, double-blind, randomized, controlled clinical trial to assess the safety and efficacy of plasticity-based, adaptive, computerized cognitive remediation treatment versus a computer-based control. both the study and the cognitive remediation treatments meet the criteria of non-significant risk.

Eligibility criteria:
inclusion criteria: 1. subjects must be 18 - 50 years of age at the time of consent 2. subjects must have a diagnosis of mtbi 3. subjects must have persistent cognitive dysfunction confirmed by an objective measure (as recommended by the icd-10 definition for post-concussion syndrome) or a subjective measure (as recommended by the dsv-iv definition of post-concussional disorder). 4. subjects must be at least three months out from their most recent tbi, concussion, and/or blast exposure to minimize the effects of spontaneous recovery, as verified through participant interview. 5. subjects must be fluent english speakers. 6. subjects must have adequate sensorimotor capacity to perform the program in the judgment of the consenting clinician. exclusion criteria: 1. subjects must not have a history of penetrating head wounds or a diagnosis of moderate or severe tbi. 2. subjects must not be in-patients. 3. subjects must not have a diagnosis of an illness or condition with known cognitive consequences (e.g., schizophrenia, bipolar disorder, cancer, multiple sclerosis). 4. subjects must not show suicidal ideation as measured by the columbia-suicide severity rating scale (c-ssrs). 5. subjects must now show signs of intoxication due to current substance abuse (including alcohol and/or illegal drugs) during any in person visit. 6. subjects must not have clinically significant visual field deficits noted by the consenting staff member by direct observation or by medical history. 7. subjects must not be judged to be lacking effort. 8. subjects must not have problems performing assessments or comprehending or following spoken instructions. 9. subjects must not be enrolled in a concurrent clinical trial involving an investigational pharmaceutical, nutraceutical, medical device, or behavioral treatment for tbi that could affect the outcome of this study.

Keywords: mild traumatic brain injury cognitive remediation computer
tislelizumab in combination with sitravatinib in participants with locally advanced or metastatic non-small cell lung cancer

Conditions: Non-Small Cell Lung Cancer (NSCLC)

Summary: the purpose of this study is to evaluate the efficacy and safety of tislelizumab in combination with sitravatinib compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer (nsclc) who have disease progression following platinum-based chemotherapy and anti-programmed cell death protein-1 (pd-1)/programmed cell death ligand-1 (pd-l1) antibody, with the anti-pd-(l)1 antibody administered in combination with or sequentially before or after the platinum-based chemotherapy.


Eligibility criteria:
key inclusion criteria: 1. metastatic or unresectable locally advanced histologicallyor cytologically confirmed non-small cell lung cancer (ncslc), not amenable to treatment with curative intent 2. able to provide archival/fresh tumor tissues for biomarker analysis to assess pd-l1 expression and other biomarkers. 3. no known epidermal growth factor receptor (egfr) or b-raf proto-oncogene (braf) sensitizing mutation, or anaplastic lymphoma kinase (alk) rearrangement or ros proto oncogene 1 (ros1) rearrangement 4. radiographic progression per response evaluation criteria in solid tumours (recist) v1.1 on or after anti-pd-(l)1 containing therapy for locally advanced and unresectable or metastatic nsclc. 5. no prior anticancer therapy having the same mechanism of action as sitravatinib (eg, tyrosine kinase inhibitor with a similar target profile or vascular endothelial growth factor (vegf)- or vegfr inhibitor) 6. at least 1 measurable lesion as defined based on recist v1.1 by investigator key exclusion criteria: 1. has received docetaxel as monotherapy or in combination with other therapies. 2. squamous nsclc with central cavitation, or nsclc with hemoptysis (\> 50 ml/day) 3. participants with tumor shown by imaging to be located around important vascular structures or if the investigator determines that the tumor is likely to invade important blood vessels and may cause fatal bleeding. 4. active leptomeningeal disease for metastatic nsclc, or uncontrolled or untreated brain metastasis. 5. active autoimmune diseases or history of autoimmune diseases that may relapse. note: other protocol defined inclusion/exclusion criteria may apply.
splinting for dupuytren's contracture release

Conditions: Dupuytren's Disease

Summary: this study is comparing two different kinds of splints for patients who have had a surgical contracture release of dupuytren's disease. it compares a static splint and a dynamic splint.


Eligibility criteria:
inclusion criteria: * 18 years or older * males and females with dupuytren's contracture * patients with contracture of less than 30 degrees of mcp contractions and no contractions of the ip joints exclusion criteria: * previous surgical treatment for dupuytren's * contracture of mcp greater than 30 degrees * contraindications for dynamic splinting (upper limb amputees, paresis, ect.)
use of bleomycin in the sclerotherapy of lymphatic malformations for pediatric patients

Conditions: Lymphatic Malformation

Summary: bleomycin has nowadays been more and more widely used in the sclerotherapy of lms, which has been proven to be primarily dose dependent. the investigators aim to compare the efficacy and safety of different concentrations of bleomycin in the sclerotherapy of lms for pediatric patients.

lymphatic malformations (lms) are vascular anomalies that arise from abnormal embryonic development of the lymphatic system and might present as dilated lymphatic channels or cysts lined by lymphatic endothelial cells. with an estimated incidence of approximately 1/4000-1/2000, lms can occur at any site in the lymphatic system, in which head, neck and axilla were mostly detected and have been reported to account for over 75%. based on the location and size of the lesion and the extent of involvement, lms may be asymptomatic with incidental detection, or chronic abdominal pain and distension due to their compression of surrounding structures, or critical and even fatal secondary to their volvulus, hemorrhage, infection and rupture. surgical excision is a definitive treatment for lms, while it may be difficult at times because of the infiltrative nature of the lesions, leading to a high incidence of complications like vital organ injuries, nerve injuries, bleeding, infection scar formation, and recurrences. sclerotherapy is a simpler alternative to tedious surgical excision treatment for lms and avoids the complications related to surgery. as an anticancer drug extracted from streptomyces verticillus, bleomycin has been more and more widely used in the sclerotherapy of lms for pediatric patients, which has been proven to be primarily dose dependent. however, the optimum concentration of bleomycin in the sclerotherapy of lms for pediatric patients has not been strictly validated, due to the lack of high-quality rct studies. the investigators aim to compare the efficacy and safety of different concentrations of bleomycin in the sclerotherapy of lms for pediatric patients.

Eligibility criteria:
inclusion criteria: * male or female participants less than 14 years of age at the time of informed consent/assent form was signed. * participants whose parents have voluntarily given written consent and participants who provided assent (if applicable) after the study has been explained to them. * participants with lms of all sites measured and confirmed via imaging at screening, with rapid progression, resluting in obvious symptoms or dysfunction, which could not be radically resected and could be treated by sclerotherapy. exclusion criteria: * penicillin allergy. * vascular tumors or combined vascular malformations. * participants who may have had surgical or sclerotherapy treatment by other hardeners. * lms growing slowly, without obvious symptoms or dysfunction, which does not need to be treated prematurely.

Keywords: lymphatic malformation bleomycin sclerotherapy intracystic injection high-dose concentrations low-dose concentrations
multi-center study on therapy-oriented molecular subtyping of hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: the purpose of this study is to establish molecular subtyping of hcc.

hepatocellular carcinoma is one of the most common malignant tumors in the world with high incidence and mortality. liver transplantation is the most effective treatment for hcc and is in high demand in china. however, recurrence of hcc among liver transplantation recipients is still a great challenge and threat to the survival of recipients. so it is of great significance to establish molecular subtyping of hcc and achieve precise selection of recipients. based on large scales of samples, the investigator's study aims to establish multi-omics characteristic profiles of liver transplantation for hcc in integration of apparent biological characteristics, clinical management and prognostic information by utilizing genomics, transcriptomics and proteomics, etc. this study will contribute to the therapy-oriented molecular subtyping of hcc.

Eligibility criteria:
inclusion criteria: liver transplantation due to hcc within hangzhou criteria exclusion criteria: liver transplantation due to hcc beyond hangzhou criteria liver transplantation due to other disease except hcc multiple organ transplantation
study of chronic obstructive pulmonary disease (copd) exacerbations in spain

Conditions: COPD

Summary: ecos is a cross-sectional, observational, longitudinal, multicenter study enrolling 100-200 patients during a copd exacerbation.

patients will be followed for 12 months. information to be collected includes clinical, analytical, immunological, microbiological, hemodynamic, imaging, environmental, social and other blood markers of inflammation (il-8, il-6, tnf, tnf-alpha, endothelin-1, slpi, il10, tgf-beta and markers oxidative stress (teac)), and sputum (cell count, il-6, il-8, slpi, et 1, il10). each center will collect clinical data, blood gas, microbiological and functional data for their patients, which will be centralized through the website of the red respira (www.redrespira.net). a frozen serum sample and another of frozen sputum supernatant will be sent to the coordinating center (palma de mallorca). statistical analysis will include descriptive statistics: mean, standard deviation and range. comparison of quantitative variables to be assessed using student's t-test and anova. correlations between variables will be performed using bivariate analyzes (pearson's linear correlation coefficient) and multivariate (multiple regression) analyses, among others.

Eligibility criteria:
inclusion criteria: * men and women * ages 40-80 years * diagnosis of copd (according to ats/ers consensus guidelines) * smoking history ≥ 10 pack years * hospitalization for exacerbation of copd exclusion criteria: * pneumonia. * pneumothorax. * severe comorbidities, such as: * -advanced cancer. * -pulmonary tuberculosis, which affects more than one third of the total lung parenchyma. * -pneumonectomy. * -previous diagnosis of left heart failure. * -cardiomyopathy with ventricular dysfunction (ejection fraction \<45%). * -chronic inflammatory diseases such as asthma, rheumatoid arthritis, pulmonary fibrosis and autoimmune diseases. * mechanical ventilation. * existence of an exacerbation of copd in the 4 weeks prior to admission. * mrsa. * history of thoracic/lung surgery in the past two years * general weakness/malaise (difficulty in walking, lack of autonomy, etc.). that substantially hinders participation in the study, regardless of their willingness to participate. * mental incapacity according to the investigator judgment. * not resident in the province in which the hospital is located. * not fluent in spanish * allergy to iodinated contrast * morbid obesity (bmi\> 40)

Keywords: biomarkers exacerbations copd
chocolate for patients with chronic kidney disease

Conditions: Chronic Kidney Disease

Summary: chocolate is a widely appreciated foodstuff with historical appreciation as food from the gods. it is a rich source of (poly)phenolics, which have several proposed salutogenic effects, including neuroprotective anti-inflammatory, antioxidant, and cardioprotective properties. this study will evaluate the potential salutogenic contribution of chocolate intake, to mitigate inflammatory and oxidative burden in chronic kidney disease patients.

this study is evaluating patients with ckd on a regular hd program randomized in the chocolate group and control group. the chocolate group is receiving 40g of dark chocolate per day for 2 months and the control group is not receiving any intervention. peripheral blood mononuclear cells (pbmc) are being isolated for expression of nrf2, nf-kb, and nadph quinone oxidoreductase 1 (nqo1) by a quantitative real-time polymerase chain reaction. antioxidant enzymes activity (catalase-cat and glutathione peroxidase-gpx), high-sensitivity c-reactive protein (hs-crp) will be assessed using an enzyme-linked immunosorbent assay (elisa).

Eligibility criteria:
inclusion criteria: * clinical diagnosis of chronic kidney disease * hemodialysis patients for more than 6 months * aged 18 years or older exclusion criteria: * patients pregnant * smokers * using antibiotics in the last 3 months * autoimmune diseases * clinical diagnosis of infectious diseases * clinical diagnosis of cancer * clinical diagnosis of aids